Accentia Biopharmaceuticals has entered a strategic agreement with Baxter Healthcare providing Accentia the exclusive, worldwide right to purchase Baxter’s cyclophosphamide — marketed under the brand name Cytoxan — for the treatment of autoimmune diseases, including multiple sclerosis. Cyclophosphamide is the active drug used in Accentia’s Revimmune therapy currently being developed for the treatment of a broad range of autoimmune diseases. Accentia also has the exclusive right to reference B...